News

BioDirection to Participate in 12th World Congress on Brain Injury

Diagnostic platform positioned to be first objective point-of-care blood test for concussion able to provide quantitative results in less than 90 seconds from a single drop of blood.

Mar 1, 2017

Boston, MA – — BioDirection, Inc., a privately held medical device company developing novel and rapid point-of-care products for the objective detection and monitoring of traumatic brain injury (TBI), announced today that the company will participate in the International Brain Injury Association’s 12th World Congress on Brain Injury to be held March 29 – April 1, 2017 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.

Read more...

BioDirection, Inc. Holds Pre-Submission Meeting with FDA

Diagnostic platform positioned to be first objective point-of-care blood test for concussion able to provide quantitative results in less than 90 seconds from a single drop of blood.

Nov 29, 2016

Boston, MA – BioDirection, a privately held medical device company developing novel and rapid point-of-care products for the objective detection of concussion and other traumatic brain injury (TBI), announced today that the company has successfully completed a meeting with the U. S. Food and Drug Administration (FDA) to review the company’s Tbit™ blood test Pre-Submission Package. During the meeting company representatives reviewed plans for clinical development of the Tbit™ system as a precursor to commencement of a planned pilot trial.

Read more...

BioDirection, Inc. Files Pre-Submission Package With FDA

Diagnostic platform positioned to be 1st objective, point-of-care blood test for concussion providing quantitative results in less than 90 seconds from a single drop of blood.

Oct 4, 2016

Boston, MA – BioDirection, a privately held medical device company developing novel and rapid point-of-care products for the objective detection of concussion and other traumatic brain injury (TBI), today announced that it recently filed a Pre-Submission ("Pre-Sub") Package with the FDA as a critical step toward commercialization of its proprietary Tbit™ diagnostic platform.

Read more...

BioDirection, Inc. Closes $4 Million Series B Financing

Financing to support final stages of development program for Tbit™ (traumatic brain injury test) technology, designed to aid in diagnosis of concussions and other brain injuries in less than 90-seconds at point-of-care.

Feb 3, 2016

Boston, MA – (PRNewswire) – BioDirection, Inc., a privately held medical device company developing novel and rapid point-of-care products for the objective management of concussion and other traumatic brain injury (TBI), today announced that it has closed over $4 million in a Series B Convertible Preferred Stock financing.

Read more...

BioDirection Receives SBANE Rising Star Award

Company selected among 175 nominees for its breakthrough point-of-care concussion test.

May 14, 2015

Boston, MA – May 14, 2015 — BioDirection, Inc. a developer of groundbreaking point-of care technology for the objective diagnosis, prognosis and monitoring of concussions and other traumatic brain injuries (TBI) was named the 2015 “Rising Star” from the Small Business Association of New England (SBANE) Innovation Awards. Its Tbit™ test, currently under development, will objectively diagnose concussions and other brain injuries from a single drop of blood in less than 90 seconds.

Read more...

BioDirection, Inc. Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

April 15, 2015

Boston, MA – April 15 2015 – an emerging medical device company focused on the development and commercialization of rapid, affordable point-of-care devices for the early identification of mild traumatic brain injury (concussion), announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of leading family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

Read more...

BioDirection, Inc. to Present at 5th Annual Traumatic Brain Injury Conference

Chief Scientific Officer Sergey Dryga to present the Tbit™ system: a new blood test for the rapid identification of concussion and other traumatic brain injury

April 8, 2015

Boston, MA – (BUSINESS WIRE) – BioDirection, Inc., a privately-held medical device company focused on the development and commercialization of easy-to-use, rapid, point-of-care devices for the objective identification of acquired brain injury including concussion, today announced it will present at the 5th annual Traumatic Brain Injury Conference being held in Washington, DC on April 16, 2015. The company’s Tbit™ system delivers objective information to aid in the diagnosis of a concussion from a single drop of blood in less than 90 seconds. Additionally, this technology provides emergency room physicians with new actionable data that can help in reducing unnecessary head CT scans, thereby saving time and expense while eliminating radiation exposure to the patient.

Read more...

BioDirection, Developer of Concussion Diagnostic Device, Selected as Finalist in Medtech Innovation Competition

New Tbit™ platform, a rapid, point-of-care diagnostic device for concussion, has been selected as a finalist in Startup Showdown Contest

April 2, 2015

Boston, MA – (BUSINESS WIRE) – BioDirection, Inc. announced today that its new Tbit™ platform, a rapid, point-of-care device for the objective identification of mild traumatic brain injury (concussion), has been selected by the Medical Device and Diagnostic Industry Journal (MDDI) as a finalist in its first ever Startup Showdown Competition. BioDirection’s Tbit™ platform utilizes patented bio-nanowire technology that can detect and measure minute levels of “biomarker” proteins released from the brain after a concussion. The technology provides first-in-class critical and objective information to aid in the diagnosis of a concussion from a single drop of blood in less than 90 seconds.

Read more...

Eric B. Goorno Joins BioDirection, Inc. as President & CEO

Proven Medical Device Executive to Lead Commercialization of Breakthrough Technology for Objective Identification of Concussion

October 23, 2014

Tucson, AZ – October 14, 2014 — BioDirection, Inc., an emerging medical device company focused on the development and commercialization of rapid, low-cost point-of-care devices for the early identification of mild traumatic brain injury (concussion) announced today that Eric B. Goorno has joined the Company as President & Chief Executive Officer. The new CEO will reside at the company’s headquarters in Massachusetts. Former CEO and Founder Brian McGlynn will transition to Director, Chief Technical Officer and Executive Vice President.

Read more...

BioDirection Completes $3.95 Million Series A Financing

Rapid Point of Care Testing for Mild Traumatic Brain Injury (Concussion)

August 19, 2013

Tucson, AZ – (BUSINESS WIRE) – BioDirection, Inc., a developer of point-of-care brain injury screening and monitoring devices to separate minor head injuries from mild traumatic head injury, announced that it recently completed a $3.95 million Series A financing. Funds will be used to complete the miniaturization of the Company's innovative biosensor test platform and position the company for an initial product launch later this year.

Read more...

BioDirection Obtains Exclusive Technology Rights from Nanosys, Inc.

BioDirection Obtains Exclusive Technology Rights from Nanosys, Inc.

March 13, 2012

Tucson, AZ – (BUSINESS WIRE) – BioDirection, Inc., a developer of point-of-care brain injury screening devices to separate minor head injuries from mild traumatic head injury, announced that it has signed an exclusive license agreement with Nanosys, Inc., an advanced materials architect, for an extensive portfolio of Harvard University generated nanowire patents and patent applications.

Read more...

BioDirection is always searching for new opportunities. Contact us today with any questions or inquiries.